If you’re a U.S. patient looking at Ozempic or Mounjaro through a Canadian pharmacy, the market you’re comparing prices in looks very different than it did a year ago. Generic semaglutide arrived in Canadian pharmacies in May 2026 and pulled the floor out from under brand-name pricing, which changes the math on which drug makes sense for you. The two drugs are also no longer approved for the same things north of the border. One now covers children as young as 10. The other carries heart and kidney indications the first one does not have.
Price is only one variable, and it is the one that has moved the most in your favor. Here is what actually separates these two drugs in Canada in 2026, and what it means for what you’ll pay and how you’ll order.
Quick Answer
Mounjaro (tirzepatide) lowers blood sugar more and produces more weight loss than Ozempic (semaglutide) when the two have been compared directly. Ozempic carries Health Canada-approved indications for cardiovascular and kidney risk reduction that Mounjaro does not. And since generic semaglutide launched, the Ozempic molecule has become far cheaper than the Mounjaro molecule, with no generic tirzepatide anywhere on the horizon.
If cost is the deciding factor, semaglutide wins and it is not close. If maximum blood sugar and weight effect is the goal, tirzepatide wins. If you have established heart disease or chronic kidney disease, the approved evidence points to Ozempic.
What Each Drug Is Approved For in Canada
| Ozempic | Mounjaro | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| How it works | Acts on one gut hormone pathway (GLP-1) | Acts on two gut hormone pathways (GIP and GLP-1) |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Type 2 diabetes | Yes, adults | Yes, adults and children 10 to 17 |
| Cardiovascular risk reduction | Yes, for adults with type 2 diabetes and established heart or kidney disease | No |
| Kidney outcomes | Yes, for adults with type 2 diabetes and chronic kidney disease | No |
| Chronic weight management | No (that is Wegovy) | No (that is Zepbound) |
| Delivery | Multi-dose pre-filled pen | Multi-dose KwikPen |
| Generic available in Canada | Yes, since May 2026 | No |
This is where a lot of comparison articles get sloppy, because the brand names do not map cleanly between countries.
Neither drug is approved for weight loss in Canada. Semaglutide’s weight-management brand is Wegovy. Tirzepatide’s is Zepbound, which Health Canada authorized for chronic weight management and which has been on the Canadian market since 2025. Doctors do prescribe both Ozempic and Mounjaro off-label for weight, which is legal and common, but it is not what the labels say.
Two label differences are worth pausing on.
First, the Ozempic product monograph authorized by Health Canada in April 2026 lists three separate approved uses: blood sugar control in type 2 diabetes, reducing the risk of heart attack, stroke and cardiovascular death in adults who also have established heart disease or chronic kidney disease, and slowing kidney decline in adults with type 2 diabetes and chronic kidney disease. Health Canada granted that heart indication on the strength of four large outcome trials involving more than 9,800 patients treated with semaglutide. Mounjaro’s Canadian label makes no equivalent claim.
Second, Mounjaro went the other direction on age. In July 2026, Eli Lilly Canada announced Health Canada authorization for use in children aged 10 to 17 with type 2 diabetes. Ozempic remains adults-only in Canada. Its product monograph states it is not indicated for patients under 18.
How the two drugs compare
When researchers have put these two drugs head-to-head, tirzepatide has come out ahead on the two numbers patients care about most: blood sugar and weight. That result has held up across more than one study, and it is consistent enough that most doctors treat it as settled.
The heart question turned out differently. Tirzepatide was tested against another well-established diabetes injection to see whether it offered better protection against heart attacks and strokes. It matched that drug. It did not beat it. Ozempic, meanwhile, has heart and kidney protection written into its Canadian approval, which is a higher bar than simply performing well in a trial.
Two things are worth knowing about how these comparisons were run, because they cut against the headline. The direct diabetes comparison tested Ozempic at a lower maximum dose than the one now available in Canada, so the real-world gap today is probably narrower than that study suggests. And the widely quoted weight-loss comparison did not test Ozempic and Mounjaro at all. It tested the higher-dose weight-management versions of the same two molecules, Wegovy and Zepbound. The findings from all three studies were published in the New England Journal of Medicine.
Here is the practical summary.
| Ozempic | Mounjaro | |
|---|---|---|
| Blood sugar lowering | Strong | Stronger when compared directly |
| Average weight loss | Substantial | Greater on average |
| Heart protection | Approved by Health Canada for this use | Matched an established comparison drug, but not an approved use |
| Kidney protection | Approved by Health Canada for this use | Not an approved use |
| Depth of outcome evidence | Deeper and more specific | Strong on blood sugar and weight |
| Time to reach full dose | About three months | About five months |
Dosing Schedules Compared
| Ozempic | Mounjaro | |
|---|---|---|
| Starting dose | 0.25 mg weekly for 4 weeks (a starter dose, not yet a treatment dose) | 2.5 mg weekly for 4 weeks (a starter dose, not yet a treatment dose) |
| First treatment dose | 0.5 mg weekly | 5 mg weekly |
| Step-up increases | To 1 mg, then 2 mg, at least 4 weeks apart | In 2.5 mg steps, at least 4 weeks apart |
| Maximum dose | 2 mg weekly | 15 mg weekly |
| Available strengths | Pens delivering 0.25 or 0.5 mg, 1 mg, or 2 mg | 2.5, 5, 7.5, 10, 12.5 and 15 mg |
| Missed dose window | Take within 5 days, otherwise skip it | Take within 4 days, otherwise skip it |
| Changing injection day | Allowed if at least 2 days between doses | Allowed if at least 3 days between doses |
| Storage after first use | Up to 8 weeks | Refrigerated, or up to 21 days below 30°C |
Both are once-weekly injections under the skin of the abdomen, thigh or upper arm, taken with or without food. The step-up schedules differ meaningfully. Mounjaro takes about five months to reach its maximum dose, Ozempic about three.
Ozempic figures come from the Health Canada-authorized Ozempic product monograph. Mounjaro figures come from the Mounjaro product monograph and Health Canada’s summary basis of decision.
One practical note catches people switching between the two. Mounjaro’s KwikPen holds four weekly doses, so one pen equals one four-week cycle at a fixed strength. Ozempic pens vary. Some deliver four doses, some six or eight, depending on strength and configuration. Read the carton before assuming one pen equals one month. If you are new to the KwikPen, our step-by-step guide to using Mounjaro covers the mechanics.
Ozempic vs Mounjaro in Canada: What They Cost
How the Canadian market changed in 2026
- January 4, 2026
Novo Nordisk loses Canadian exclusivity on semaglutide, years earlier than in the U.S.
- April 28, 2026
Health Canada becomes the first G7 regulator to approve a generic semaglutide.
- May 1, 2026
A generic from Apotex is approved for type 2 diabetes.
- June 29, 2026
A generic carrying the chronic weight management approval follows.
There is no generic tirzepatide. None is approved, and none is under Health Canada review. Anything marketed as generic Mounjaro is not a Health Canada-approved product, and compounded tirzepatide sold online is a genuine counterfeit risk.
Cost order, least to most expensive
- Same active ingredient as Ozempic
- Same pen strengths available
- Held to Health Canada's bioequivalence standard
- Sits below Mounjaro at every dose level
- Approved for heart and kidney protection
- Established, stable supply chain
- No generic competition
- Stronger blood sugar and weight effect
- Cost rises at higher strengths
Because pricing moves with exchange rates, pharmacy source and availability, current prices are listed on each product page rather than here. Check them before you order.
Availability: what is actually on the shelf
Approval and availability are not the same thing, and this is the single most overlooked part of the comparison.
Mounjaro vials are in an open shortage. Health Canada’s drug shortage database shows active shortage reports for multiple Mounjaro vial strengths with no estimated end date. Eli Lilly Canada’s own comment on those reports is unambiguous: remaining vial inventory is reserved for patients who cannot use the KwikPen, no further vials are being released to wholesalers, and KwikPen supply is being prioritized going forward. All KwikPen strengths from 2.5 mg to 15 mg are listed as available.
If you have been on Mounjaro vials and draw your doses with a syringe, plan for that supply to keep tightening, and talk to your prescriber about the KwikPen. Product availability at any given pharmacy, including ours, depends on what distributors can source.
Ozempic supply is stable, and generic semaglutide has added capacity from several manufacturers rather than relying on a single supply chain. That is a meaningful practical advantage after the shortages of 2023 and 2024, when Health Canada advised prescribers against starting new patients on Ozempic at all.
Coverage inside Canada is effectively diabetes-only. Provincial plans cover both drugs for type 2 diabetes under limited-use or special-authority criteria, and neither is covered for weight management. That matters less for U.S. buyers paying cash, but it explains why Canadian prices moved before U.S. ones. In Canada, list prices flow directly into public reimbursement.
Side effects and contraindications
The side effect profiles are close cousins.
Common side effects (both drugs):
- Nausea (most common, affects a meaningful minority of patients)
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Reduced appetite
Mostly during the step-up phase, mostly mild to moderate.
Shared warnings:
- Thyroid tumors seen in rodent studies; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2
- Contraindicated in pregnancy and breastfeeding
- Pancreatitis, gallbladder disease
- Kidney injury following severe dehydration
- Aspiration risk under general anesthesia (both slow stomach emptying)
Two key differences:
- Ozempic: carries a warning about diabetic eye disease. Patients with existing retinopathy should be monitored when starting.
- Mounjaro: reduces the effectiveness of oral contraceptives. A non-oral or barrier method is recommended for four weeks after starting and after each dose increase. Semaglutide does not carry this interaction.
For a fuller breakdown on either drug, see our posts on the pros and cons of Ozempic and the benefits of Mounjaro.
So which one?
A few situations where the answer is reasonably clear.
Established heart or kidney disease alongside type 2 diabetes. Ozempic is the approved option, backed by outcome trials Mounjaro has not matched. When tirzepatide was tested on heart outcomes it held its own, but it did not do better.
Blood sugar well above target despite a maximum dose of semaglutide. Tirzepatide has more headroom, both in raw effect and in the number of dose steps available above where Ozempic tops out.
Cost is the constraint. Generic semaglutide, without much debate. It is the same molecule as Ozempic, held to the same Health Canada standard, at a fraction of what tirzepatide costs.
A teenager with type 2 diabetes. Mounjaro is the only one of the two with a Canadian approval for that age group.
Weight loss is the primary goal. Neither is approved for it in Canada. Both get prescribed off-label, and tirzepatide has the stronger data. But if weight management is the actual objective, the honest answer is that Wegovy and Zepbound are the drugs designed and licensed for it. Our guides on who qualifies for Ozempic and eating well on Mounjaro are worth reading before you commit either way.
And if you have not tried metformin yet, that conversation usually comes first for people with type 2 diabetes. We cover the trade-offs in metformin vs Ozempic.
Ordering From Canada as a U.S. Patient
Valid prescription required
Both drugs require a valid prescription from a licensed prescriber before your order can be filled.
4 to 10 business day delivery
Cold-chain medications ship in temperature-controlled packaging. Customs holds can extend delivery.
Signature required
A signature is required on delivery for added security.
Inspect on arrival
Check the outer box for dents or tears before opening your package.
If you also manage insulin therapy, both of these drugs are frequently used alongside basal insulin, with dose reductions to lower the risk of low blood sugar. You can browse insulin brands available from Canada in the same order.
Frequently Asked Questions
Articles you may also be interested in
